Who should receive recombinant factor VIII?
Recent guidelines published by the United Kingdom Haemophilia Centre Directors' Organisation state that recombinant factor VIII constitutes the treatment of choice for all patients with haemophilia A. However, certain categories may have to be accorded priority as financial resources are limited. The general order of priority for the introduction of recombinant factor VIII is (1) previously untreated patients, (2) human immunodeficiency virus (HIV)- and hepatitis C-negative patients, (3) HIV-negative, hepatitis C-positive patients and (4) patients seropositive for anti-HIV.
Giangrande
P L
PL
Oxford Haemophilia Centre, Churchill Hospital, UK.
D016527:Drug Costs; D005169:Factor VIII / Q000191:economics / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000191:economics / Q000627:therapeutic use*; D006113:United Kingdom
D011994:Recombinant Proteins; D005169:Factor VIII